AKCA Market Cap History
Below is a table of the AKCA market cap history going back to 7/14/2017:

Date AKCA Market Cap
7/14/2017479.62M
8/2/20171.03B
11/1/20171.15B
2/20/20181.33B
4/30/20182.23B
7/31/20182.71B
10/31/20181.99B
2/20/20192.35B
5/2/20192.36B
8/1/20192.01B
8/5/20192.91B
10/31/20191.72B
2/20/20201.86B
4/29/20201.81B
7/29/20201.18B

Also see: AKCA Shares Outstanding History
and AKCA YTD Return
AKCA Historical Market Cap:
+34.59% CAGR
AKCA Historical Market Cap: +34.59% CAGR

Mouse over chart for data details
7/14/2017 ...7/29/2020
Akcea Therapeutics is a commercial stage biopharmaceutical company developing and commercializing medicines to treat patients. Co. is focused on commercializing its approved therapies, TEGSEDI and WAYLIVRA. TEGSEDI is indicated to treat adults with the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, and has been approved and launched in the United States, the European Union, and Canada as well as approved in Brazil. WAYLIVRA is indicated as an adjunct to diet to treat adult patients with genetically confirmed familial chylomicronemia syndrome, who are at high risk for pancreatitis, for whom response to diet and triglyceride lowering therapy has been inadequate. We show 15 historical shares outstanding datapoints in our AKCA shares outstanding history coverage, used to compute AKCA market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing AKCA market cap history over the course of time is important for investors interested in comparing AKCA's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of AKCA versus a peer is one thing; comparing AKCA market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like AKCA can fluctuate over the course of history. With this page we aim to empower investors researching AKCA by allowing them to research the AKCA market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for AKCA:
AKCA SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Akcea Therapeutics (AKCA) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

AKER Market Cap History
AKRX Market Cap History
ALBO Market Cap History
ALC Market Cap History
ALDR Market Cap History
ALDX Market Cap History
ALGN Market Cap History
ALIM Market Cap History
ALKS Market Cap History
ALNA Market Cap History
More Healthcare companies »

 

AKCA Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.